Pembro-GVD R/R cHL five-year f/u @bloodjournal.bsky.social
- 39 pts; 41% 1° refractory
- ORR 100% (CR 95%)
- 95% proceeded to ASCT
- 5-yr PFS 91%, OS 94% (!!!)
Long-term remissions/cures with CPI + ASCT in R/R cHL. Interesting question remains re: 2nd-line regimens with use of frontline CPI. #lymsm

S1826 outcomes (& tox profile) comparable to trial in RW older adults. #lymsm
haematologica.org/article/view...
cc @uduranimd.bsky.social @hjcherng.bsky.social @priyankapophalimd.bsky.social @tvoorheesmd.bsky.social

Real-world N-AVD older cHL #lymsm
- 327 pts: 81 (25%) 60+ yr, med age 70
- EOT ORR 88% (CR 83%)
- 1-yr PFS 92%, OS 99%
- OS inferior if age 60+ (not surprising)
- GCSF 82%, FN 12% (52% G3+ neutropenia), infx 27%
- irAEs 29%, nivo d/c'd 17%, 10% all tx d/c'd for AEs

Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...

📣 LESS THAN A MONTH BEFORE THE START OF #ESHLYMPHOMA2026
Don't delay, register now ➡ bit.ly/42eJ3s6
5th How to Diagnose and Treat Lymphoma
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
Oct. 29-31, 2026/Prague, Czech Republic
#ESHCONFERENCES #Haematology #LYMsm #Lmsm

📰 Just in: Epcoritamab plus R-CHOP improved PFS vs R-CHOP alone in newly diagnosed DLBCL, meeting the primary end point of the phase 3 EPCORE DLBCL-2 trial #lymsm #oncology

Dive into the topline findings: www.onclive.com/view/epcorit...

Last week's #OncFive:

✅ Pirtobrutinib OK'd in 1L CLL/SLL #lymsm #leusm
🎗️ Priority review: elinzanetant for breast cancer #bcsm
🩸 Tabelecleucel BLA resubmitted in EBV+ PTLD
🫁 Savolitinib+osimertinib NDA in MET+ NSCLC #lcsm
🫁 Zipalertinib NDA starts in NSCLC

🔗: www.onclive.com/view/the-onc...

WATCH 👀: Brad S. Kahl, MD, of @washumedicine.bsky.social discusses EA4181 findings, whether cytarabine is needed with BTK inhibition, and the future of chemotherapy-free care in mantle cell lymphoma.

Full video ➡️: www.onclive.com/view/dr-kahl...

#oncology #lymsm @societyofhemonc.bsky.social

Many thanks to @cudeptofmedicine.bsky.social for featuring our patient-reported outcomes work in this year's Annual Report! #lymsm #medsky #oncsky cc @cuanschutz.bsky.social @cucancercenter.bsky.social @accordsresearch.bsky.social

“We can tailor treatment and make nuanced decisions for the individual patient in front of us,” Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, of @petermaccc.bsky.social said of CLL management. @societyofhemonc.bsky.social #SOHO2026 #lymsm #hematology

Full interview: www.onclive.com/view/cll-tre...

🎙️ On this #OncologyUnplugged episode, Chandler Park, MD, and Joshua Brody, MD, note evolving treatments for B-cell lymphomas. #lymsm #hematology

Watch the episode on our site or listen on your favorite podcast platforms: www.onclive.com/view/fast-mo...

📈 The primary end point of CELESTIMO was met with mosunetuzumab plus lenalidomide showing a statistically significant PFS improvement vs rituximab plus lenalidomide in R/R follicular lymphoma.

Read more here 📰: onclive.com/view/mosunet...

#lymsm #oncology #phase3

Could CEACAM1 represent a potential therapeutic target in mantle cell lymphoma? Tycel Phillips, MD, of @cityofhope.bsky.social breaks down preclinical findings and why future research and development could center around the glycoprotein #lymsm #oncology www.onclive.com/view/high-ce...

📈Updated data from the phase 3 ECHO trial showed improved efficacy for acalabrutinib plus BR in frontline MCL, providing insight about treatment sequencing.

Full details ➡️: www.onclive.com/view/echo-sh...

#SOHO2026 #lymsm #oncology @societyofhemonc.bsky.social

🤔 Lower risks of TLS were shown for venetoclax-based regimens in patients with CLL compared with MCL, according to a real-world analysis.

Full details 📰: onclive.com/view/venetoc...

#leusm #lymsm #oncology #SOHO2026
@societyofhemonc.bsky.social

Elated to share that our NCI K08 has been selected for funding! Deeply grateful to @hawkeyestudts.bsky.social and my colleagues @cuhematology.bsky.social @accordsresearch.bsky.social for their persistence and coaching in bringing this lymphoma PRO-focused training award to fruition. #lymsm

It’s an honor to be captain of Team @roswellpark.bsky.social and a Board of Trustee for @bloodcancerunited.bsky.social
I need your help raising $ for patients, families and critical research for blood cancer. These pennies still matter! #lymsm #mmsm #leusm #bmtsm
pages.lls.org/ltn/wcny/Buf...

2️⃣ conferences at once! Get ready for #SOHO2026 in Houston and #WCLC26 in Seoul!
🤠 Over the next few days, we’ll be covering the two conferences in-depth with expert insight all on our site! 🇰🇷
@societyofhemonc.bsky.social @iaslc.bsky.social #lcsm #leusm #mmsm #mpnsm #lymsm #oncology #hematology

🔬 Stronger prognostic and predictive value was shown for ctDNA testing with the Signatera assay vs standard PET/CT imaging in patients with lymphoma.

Full details 📰: www.onclive.com/view/real-wo...

#oncology #lymsm